Scott Clarke is the founder of Tizona Therapeutics. Tizona Therapeutics has raised $70M in total funding. Latest round: Series D.
Scott Clarke started as CEO of Tizona Therapeutics in January 2019. Previously, he was Global Head of Oncology Partnering and Head of Asia and Emerging Markets Partnering at Roche. He also held roles of increasing responsibility at BioMarin Pharmaceutical, Inc., most recently as Senior Vice President of Product Development.
Full founder directory · Investor directory · Company funding database · Fundraising library